Previous 10 | Next 10 |
Aethlon Medical ( NASDAQ: AEMD ) on Monday said the U.S. FDA had approved a change in the protocol of the company's ongoing trial evaluating its blood filtration system to treat patients with severe COVID-19. AEMD said the change in protocol eliminates the inclusion cr...
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment PR Newswire Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study SAN DIEGO ...
Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...
Aethlon Medical, Inc. (AEMD) Q4 2022 Results Conference Call June 28, 2022 04:30 PM ET Company Participants Dr. Chuck Fisher - CEO Jim Frakes - CFO Dr. Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Vernon Bernardino - H.C. Wainwright Anthony Vendetti -...
Aethlon Medical press release (NASDAQ:AEMD): FY GAAP EPS of -$0.71 misses by $0.11. Revenue of $0.29M (-56.1% Y/Y) misses by $0.72M. At March 31, 2022, Aethlon Medical had a cash balance of approximately $17.1 million. Shares +0.85%. For further details see: Aethlon Medical GAAP EPS of ...
Aethlon Medical (NASDAQ:AEMD) is scheduled to announce Q4 earnings results on Tuesday, June 28th, after market close. The consensus EPS Estimate is -$0.14 (+78.5% Y/Y) and the consensus Revenue Estimate is $0.72M (+9.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revis...
AEMD, OTCPK:ANCUF, AVAV, OTC:OIBZQ, PRGS, XAIR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022 PR Newswire SAN DIEGO , June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer...
Addex Therapeutics (ADXN) -36% after terminating lead program. ToughBuilt Industries (TBLT) -28%. Advent Technologies (ADN) -13%. Comera Life Sciences (CMRA) -9%. Sidus Space (SIDU) -8%. Aethlon Medical (AEMD) -8%. Rhythm Pharmaceuticals (RYTM) -4% after FDA rejects Rhythm...
The latest outbreak of monkeypox has some scratching their heads. What more can 2022 bring to the market? We’ve seen a stock market crash, the hopeful recovery from COVID-19, record inflation, rising rates, and now this. But it has placed some penny stocks in focus. On Wednes...
News, Short Squeeze, Breakout and More Instantly...
2024-06-28 12:40:00 ET SAN DIEGO - June 28, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. ( Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal ye...
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update PR Newswire Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Na...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...